Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Journal Article Scrutiny Increases In Recent FDA Ad Division Letters

Executive Summary

FDA is scrutinizing use of published studies in promotional campaigns more closely, recent untitled letters issued by the agency's Division of Drug Marketing, Advertising & Communication indicate.

You may also be interested in...



FDA Misgivings About Reprints Would Not Make Them "False" - WLF Lawyer

FDA will not be permitted to object to off-label reprints as "false and misleading" when the agency finds technical problems with an article, attorney Daniel Troy (Wiley, Rein & Fielding) asserted at an Aug. 18 Washington Legal Foundation forum on the impact of the recent WLF v. Henney off-label information dissemination ruling.

Compliance Claim Guidance Being Considered By FDA - DDMAC's Palmer

Promotional "compliance claims" may be the next subject tackled in a draft guidance from FDA's Division of Drug Marketing, Advertising & Communications, Branch Chief Leah Palmer told the Drug Information Association annual meeting.

Vivus Is Preparing Revised TV Ads For Muse Following FDA NOV Letter

Vivus is in discussions with FDA regarding revised TV broadcast ads for its erectile dysfunction therapy, Muse (alprostadil), following receipt of a notice of violation letter from the agency objecting to certain aspects of the company's TV and print ad campaigns.

Related Content

UsernamePublicRestriction

Register

PS035407

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel